PharmacoEconomics & Outcomes News 804, p10 - 2 Jun 2018 Controlled temperature chain cost saving for HBV prevention A controlled temperature chain (CTC) for the delivery of the birth dose of hepatitis B vaccine appears to be cost saving in the prevention of hepatitis B virus (HBV) infections in many parts of the world, according to findings of a study published in The Lancet Global Health. A model was used to estimate total HBV-related disability-adjusted life-years (DALYs) and costs (vaccine delivery costs and disease-related costs) per 1000 births, with versus without the CTC, in six regions of the world (East Asia and Pacific; South Asia; Central Europe, Eastern Europe and Central Asia; North Africa and Middle East; sub-Saharan Africa; and Latin America and Caribbean) and in 72 countries. Cost effectiveness was assessed from a healthcare system perspective over a lifetime time horizon. The CTC strategy was estimated to achieve health benefits in all six regions compared with no CTC, and was cost saving in four regions: East Asia and Pacific, sub-Saharan Africa, North Africa and Middle East, and Latin America and Caribbean. Cost saving per 1000 births in these regions were $1310, $1920, $1500 and $890, respectively. Estimated incremental cost-effectiveness ratios (ICERs) for the CTC strategy versus no CTC ranged from per DALY averted per 1000 births in Central $0.15 Europe, Eastern Europe and Central Asia, to $79.72 in South Asia. The cost effectiveness of CTC was greater in countries with a higher prevalence of HBV, lower birth dose coverage, or later birth dose delivery. "A CTC outreach strategy that improves the timing and coverage of the HBV birth dose vaccination is likely to be cost-saving and reduce the burden of HBV infection associated with perinatal transmission," concluded the authors. "All the benefits of the CTC will never come to fruition if no manufacturer exists with a product licensed and prequalified for CTC use . . . global efforts to support the development of appropriate CTC incentives for manufacturers are needed; additionally, the assessment, quantification, and effective communication of the demand for CTC should be communicated to manufacturers by countries as well as other global stakeholders," said Minal Patel and Anna-Lea Kahn from the WHO, Geneva, Switzerland, in an accompanying comment published in The Lancet Global Health. * 2014 US dollars 1. Scott N, et al. Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study. The Lancet Global Health 6: e659-e667, No. 6, Jun 2018. Available from: URL: https://doi.org/10.1016/S2214-109X(18)30219-5. 2. Patel MK, et al. Game changing: hepatitis B vaccine in a controlled temperature chain. The Lancet Global Health 6: e596-e597, No. 6, Jun 2018. Available from: URL: https://doi.org/10.1016/S2214-109X(18)30233-X. 1173-5503/18/0804-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved PharmacoEconomics & Outcomes News 2 Jun 2018 No. 804
PharmacoEconomics & Outcomes News – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera